# Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

> **NCT02891850** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 225 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Sildenafil
- **DRUG:** Tadalafil

## Key facts

- **NCT ID:** NCT02891850
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-11
- **Primary completion:** 2020-01-29
- **Final completion:** 2020-03-03
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02891850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02891850, "Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02891850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*